You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《蓝筹业绩》石药集团(01093.HK)首季纯利14.72亿元人民币升26.9%
阿思达克 05-24 12:07
石药集团(01093.HK)公布截至今年3月底止首季业绩,营业额67.34亿元人民币(下同),按年升9.9%。纯利14.72亿元,按年升26.9%;每股盈利12.29分。

撇除去年同期出售附属公司收益,今年首季基础溢利14.72亿元,按年增63.3%。

期内成药业务方面录得销售收入54.8亿元,较去年同期增加9.1%,实现稳定的增长。原料产品业务方面,受惠产品价格上升,首季维生素C产品於本期录得销售收入5.24亿元,较去年同期增加22.9%。抗生素及其它产品的销售收入亦因销量上升增加31%至3.89亿元。另外,功能食品及其它业务方面,受销量下跌影响期内销售收入3.41亿元,较去年同期减少10.4%。

首季集团研发费用达6.91亿元,按年增加21.7%,约占成药业务收入的12.6%。目前在研项目约300个,其中小分子创新药40余项、大分子创新药40余项,新型制剂20余项,主要聚焦於肿瘤、自身免疫、精神神经、消化和代谢、心脑血管系统及抗感染治疗领域。目前有30个产品处於药品注册审评待批阶段,39个产品正在开展临床试验(包括31个创新药以及8个新型制剂),以及5个产品待批临床批件。

未来三年,集团预计将上市新产品60余个,其中预计市场空间超过10亿元的重磅品种将不少於15个,而纳米技术平台研发的多西他赛白蛋白纳米粒、紫杉醇白蛋白纳米粒(速溶)等产品,都是具有全球专利及极具市场价值的重磅产品。

集团现正积极物色收购及合作的机会,以加强产品管线及充分利用集团的销售平台。(el/u) ~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account